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G
iven that cardiovascular disease is a
common complication of diabetes
(1) and the leading cause of death
among people with diabetes (2,3), it is
important that we use the most effective
therapies to manage lipids, blood pres-
sure,andglycemiatoreducetherisk,pro-
gression, and impact of macrovascular
disease. Recent studies by Gaede et al. (4)
clearly demonstrated that intensive man-
agement of all risk factors, including lip-
ids, blood pressure, and glycemia, had
signiﬁcant beneﬁcial effects on cardiovas-
cular-related deaths. This intensive ther-
apywasalsofoundtobecost-effective(5).
Nevertheless, questions are now be-
ing raised regarding the importance of
glycemia relevant to the prevention
and/or progression of cardiovascular dis-
ease. To begin answering these questions,
weﬁrstneedtoask:Isthereanyreasonnot
to believe there is a link between hyper-
glycemia and cardiovascular disease?
PLENTY OF AVAILABLE
EVIDENCE— We have strong evi-
dence from large randomized controlled
trials that clearly establish a causal rela-
tionship between poor glycemic control
and the development of microvascular
disease(6,7).Whyshouldweassumethat
large blood vessels are immune to the
same damaging effect of hyperglycemia?
Weshouldnot:thereisplentyofevidence
linking hyperglycemia to macrovascular
risk.
Analysis of data from 3,642 U.K. Pro-
spective Diabetes Study subjects (for
whom complete data for potential con-
founders were available) showed a signif-
icant 14% (P  0.0001) reduction in
myocardial infarction for each 1% reduc-
tion in mean A1C (8).
An early meta-regression analysis by
Coutinho et al. (9) showed that the pro-
gressiverelationshipbetweenglucoselev-
els and cardiovascular risk extends below
the diabetic threshold. Analyzed studies
comprised 95,783 people who had 3,707
cardiovascular events over 12.4 years.
Morerecently,Levitanetal.(10)con-
ﬁrmed that hyperglycemia in the nondia-
betic range was associated with increased
risk of fatal and nonfatal cardiovascular
disease, with a similar relationship be-
tween events and fasting or 2-h plasma
glucose. In the meta-analysis of 38 stud-
ies, cardiovascular events increased in a
linear fashion without a threshold for 2-h
postprandial plasma glucose, whereas
fasting plasma glucose showed a possible
threshold effect at 99 mg/dl.
Hanefeld et al. (11) found signiﬁcant
positive trends in risk reduction for all
selected cardiovascular event categories
with treatment with acarbose, an -glu-
cosidase inhibitor that speciﬁcally re-
duces postprandial plasma glucose
excursions by delaying the breakdown of
disaccharides and polysaccharides
(starches) into glucose in the upper small
intestine.Inallofthesevenstudieswithat
least 1 year’s duration, people treated
with acarbose not only showed reduced
2-h postprandial levels compared with
control subjects, but treatment with acar-
bose was signiﬁcantly associated with a
reduced risk for myocardial infarction
and other cardiovascular events. Similar
ﬁndings have been reported in subjects
with impaired glucose tolerance who
were treated with acarbose (12).
A 2006 meta-analysis by Stettler et al.
(13) showed that efforts to improve gly-
cemia yield signiﬁcant reductions in ma-
crovascular disease in type 1 and type 2
diabetes. The beneﬁt was particularly
strong in younger patients with shorter
duration of the disease. A more recent re-
port from the Euro Heart Survey on Dia-
betes and the Heart (14) showed a
pronounced decrease in cardiovascular
events in subjects with newly diagnosed
diabetes treated with glucose-lowering
agents.
The International Diabetes Federa-
tion recently published its guideline for
managingpostprandialglucose(15),pro-
viding strong evidence regarding the role
ofpostprandialhyperglycemiaasaninde-
pendentriskfactorformacrovasculardis-
ease. Among the several studies cited in
the guideline is a report by Esposito et al.
(16), who demonstrated a reduction in
carotid intima-media thickening by re-
ducing postprandial glucose excursions.
Carotid intima-media thickening is di-
rectly related to clinical manifest cardio-
vascular disease and is associated with
increased risk for myocardial infarction
and stroke (17,18).
Although the exact mechanism by
which vascular damage occurs is not fully
understood, numerous studies support
thehypothesisofacausalrelationshipbe-
tween hyperglycemia and oxidative stress
(19–24). Oxidative stress has been impli-
cated as the underlying cause of both the
macrovascular and microvascular com-
plications associated with type 2 diabetes
(25–27).
Some propose that hyperglycemia,
freefattyacids,andinsulinresistancefeed
into oxidative stress, protein kinase C ac-
tivation, and advanced glycated end
productreceptoractivation,leadingtova-
soconstriction,inﬂammation,andthrom-
bosis (28). Acute hyperglycemia and
glycemicvariabilityappeartoplayimpor-
tant roles in this mechanism. For exam-
ple, some studies (29–31) have shown
that variability in glucose levels may be
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Regardless of the mechanism(s) be-
hind vascular damage, or whether you
even believe there is a relationship be-
tween hyperglycemia and cardiovascular
disease, perhaps the bigger question is,
“Does it really matter?”
FROM EVIDENCE-BASED TO
SOUND CLINICAL
JUDGMENT— Of course it is impor-
tant to understand as much as we can
about diabetes, its causes, and its compli-
cations. However, to debate whether hy-
perglycemia is a causal factor in the
development of cardiovascular disease
serves little purpose. Almost everyone
agrees that hyperglycemia drives the de-
velopment and progression of microvas-
cular complications. Therefore, we
should continue to treat hyperglycemia
aggressively, even though some believe
that we lack randomized control trials
(the alleged “holy grail” of research) to
prove a relationship between hyperglyce-
mia and macrovascular disease.
It is important to note, however, that
although the Diabetes Control and Com-
plicationsTrial(DCCT)(6)failedtoshow
a statistically signiﬁcant causal relation-
ship between hyperglycemia and cardio-
vascular disease because of the low rate
of macrovascular events, the DCCT/
Epidemiology of Diabetes Interventions
and Complications (EDIC) (32) study,
which followed 1,341 of the original
DCCT cohort for an additional 12 years,
showed that intensive management of
glycemia does have signiﬁcant long-term
effects on the risk of cardiovascular dis-
ease in type 1 diabetes. Whereas some
may argue that the EDIC study was not
randomized, and thus not substantive, it
can also be argued that EDIC was simply
an extension of DCCT, with long enough
duration to actually detect the impact of
glycemic control on macrovascular
disease.
If the question at hand is whether we
shouldstoptreatingtheotherriskfactors,
lipids and high blood pressure, and focus
only on glucose control, then a serious
debate would be warranted. To our
knowledge, no such therapeutic ap-
proach has been proposed.
Insummary,ourpositionisthatthere
is strong evidence supporting the causal
relationship between hyperglycemia and
cardiovascular disease. It is also our posi-
tion that diabetes and all of its associated
risk factors should be managed aggres-
sively, regardless of whether one believes
in the current strength of the evidence re-
lationship between hyperglycemia and
cardiovascular disease.
Clearly, sound clinical judgment is
neededtosetsafeandreasonablegoalsfor
diabetes management, especially in el-
derly patients and those with known car-
diovascular disease or other high-risk
factors;however,inouryoungerpatients,
aggressive treatment of all metabolic ab-
normalities with persistent titration of
medication until all goals are met is
needed.
Regardingthesigniﬁcanceofthispar-
ticular debate, we ﬁnd it somewhat con-
cerning that both the American Diabetes
Association and the American Heart As-
sociationhasactuallyspenttimeresearch-
ing and reviewing this issue (33). We
propose that more time and effort be
spent on ﬁnding ways to improve our de-
livery of care rather than focus on aca-
demic issues that have no real clinical
bearing on the way we manage diabetes.
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